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Abstract
Introduction
Studies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hep-
atitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening
intervention, outcomes and the economic modelling framework. It is therefore difficult to
compare cost-effectiveness results between studies. This systematic review aims to sum-
marise and critically assess existing economic models for HBV and HCV in order to identify
the main methodological differences in modelling approaches.
Methods
A structured search strategy was developed and a systematic review carried out. A critical
assessment of the decision-analytic models was carried out according to the guidelines and
framework developed for assessment of decision-analytic models in Health Technology
Assessment of health care interventions.
Results
The overall approach to analysing the cost-effectiveness of screening strategies was found to
be broadly consistent for HBV and HCV. However, modelling parameters and related struc-
ture differed between models, producing different results. More recent publications performed
better against a performance matrix, evaluating model components and methodology.
Conclusion
When assessing screening strategies for HBV and HCV infection, the focus should be on
more recent studies, which applied the latest treatment regimes, test methods and had
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better and more complete data on which to base their models. In addition to parameter
selection and associated assumptions, careful consideration of dynamic versus static
modelling is recommended. Future research may want to focus on these methodological
issues. In addition, the ability to evaluate screening strategies for multiple infectious dis-
eases, (HCV and HIV at the same time) might prove important for decision makers.
Introduction
The effectiveness and cost-effectiveness of screening for infectious diseases such as Hepatitis B
(HBV) and Hepatitis C (HCV) have been evaluated in a number of studies [1–3]. However,
studies are generally heterogeneous, in terms of the populations studied (e.g. different risk
groups in different countries), the screening strategies adopted (different means of testing in a
variety of clinical and community settings) and the outcomes measured (e.g. infections
detected, life-years gained and quality adjusted life-years (QALYs) gained). Studies further dif-
fer in terms of the methods employed in order to evaluate the cost-effectiveness of screening.
Cost-effectiveness results may depend on the type of economic model used and also on
assumptions made regarding model structure and input parameters. The aims of this study
were to undertake a systematic review, summarise and critically assess the existing economic
models for HBV and HCV in order to identify the main methodological differences in model-
ling approaches.
Methods
A systematic review was carried out according to the principles set out by the Campbell and
Cochrane Economics Methods Group (CCEMG) [4].
Eligibility Criteria
Studies fulfilling the following criteria were included in the systematic review:
 Population—the general population (excluding blood donors) and selected subpopula-
tions (women during pregnancy, men who have sex with men (MSM), immigrants, inject-
ing drug users (IDUs), recipients of blood transfusion and blood products and healthcare
workers (HCW)) from OECD countries.
 Intervention–testing strategies for HBV or HCV in different settings.
 Comparator–no testing or alternative testing strategies.
 Outcomes–measurement and reporting of both costs and benefits (regardless of how they
were measured).
 Study type–economic evaluation incorporating cost-effectiveness analysis.
No language restrictions were imposed during the literature search.
A structured search strategy was developed under the guidance of a specialist subject librar-
ian (S1 Text) and relevant search filters that are highly sensitive and tailored to specific data-
bases were incorporated [5]. Separate search strategies were developed for HBV and HCV
screening. A multi-facetted approach for identifying the relevant literature was carried out; the
following data sources were searched from inception to November 2011 and updated to July
2015: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature
Cost-Effectiveness of HBV and HCV Screening
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(CINHAL), Health Technology Assessment (HTA) and Economic Evaluation Database (NHS
EED), Database of Abstracts of Reviews of Effects (DARE), European Network of Health Eco-
nomics Evaluation Databases (EURONHEED). This was supplemented by using the Web of
Science database to generate a list of articles that cited identified original studies. Hand search-
ing the references of all studies meeting the inclusion criteria was also carried out.
Data Extraction/Collection process
Screening of titles and abstracts was carried out, followed by selecting relevant studies based on
a priori identified inclusion and exclusion criteria. Two independent reviewers selected and
reviewed all relevant studies and assessed their quality. Study results were systematically
extracted by one reviewer according to a pre-defined protocol and summarised in evidence
tables. Data extraction was subsequently validated independently by a second reviewer. Any
disagreement relating to the inclusion of studies, data extraction, or quality assessment between
the reviewers was resolved by discussion.
Model Critique
A critical assessment of the decision-analytic models was carried out according to the guide-
lines and framework developed for assessment of decision-analytic models in Health Technol-
ogy Assessment of health care interventions [6]. The checklist developed by Philips and
colleagues provides a structure for any critical appraisal of economic models and concentrates
on model structure. This was used in addition to the Drummond Checklist [6, 7]. A perfor-
mance matrix was developed based on the checklist developed by Philips et al. The matrix sum-
marises various elements from the checklist into twelve distinct categories in order to reflect
the overall quality of the model (S2 Text).
Results
Cost-effectiveness analyses of screening for HBV
The initial search (up to November 2011) returned 2,284 references, of which 15 studies met
the inclusion criteria (Fig 1). The literature search was subsequently updated in July 2015 and
returned 824 references. One additional study was identified (Fig 2). Studies evaluated the
cost-effectiveness of screening for HBV in Europe, North America and Australia in different
settings and populations. Five studies evaluated screening in the general population [8–12],
three studies looked at women during pregnancy [13–15], five studies analysed screening for
immigrants [16–20] and another three studies [21–23] looked at screening newborns, preado-
lescents and adolescents. Studies predominantly assessed screening strategies in combination
with vaccination and treatment.
All cost-effectiveness results have been summarised and are presented in Table 1 below.
Detailed data extraction tables are available as S1 Table.
Studies carried out in the general population mainly evaluated the cost-effectiveness of
screening versus no screening and the cost-effectiveness of different vaccination strategies. All
identified economic evaluations were based on decision-analytic models consisting of decision
trees and/or Markov models. The decision tree usually reflected the screening strategy and out-
comes were presented as ‘cases identified’ while the Markov model added the disease and treat-
ment elements with outcomes usually reflected as QALYs. The measure of health benefits
varied across studies, and cost-effectiveness was expressed as for instance: incremental costs
per case averted [11], life-years gained [8, 15, 23] or QALY gained [9, 10, 12, 16, 18, 19].
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Compared with no screening, screening for HBV in high-risk groups (prevalence>5%) of the
general population has been shown to be cost-effective in an Italian and a US study [10, 12].
Two studies (US and Belgium) used decision trees to show that screening women during
pregnancy and subsequent immunisation of infants of test-positive mothers was cost-effective
compared to no screening [13, 15]. The Belgian study was carried out from a healthcare system
perspective and cost-effectiveness was expressed as incremental costs per life-year saved [15].
The US study provided a cost and cost-effectiveness was expressed as total net costs; health out-
comes were expressed as total net costs with and without screening and vaccination, taking
into account potential adverse outcomes prevented [13]. This study reported that universal
screening of women during pregnancy and subsequent immunisation of infants compared
with no screening or vaccination was considered cost-saving in a US context (over $3 million
(US dollars) saved per 100,000 women screened).
In another study, universal screening and vaccination was also compared with selective
screening of high-risk pregnant women [14]. In the absence of a decision-analytic model or an
incremental analysis, this study carried out naïve comparisons between the costs per carrier
identified with universal and that with selective screening, and vaccination in women during
pregnancy in one antenatal clinic (N = 5,858). Thomas et al estimated that $18,394 (Australian
dollars; AUD) would be required to detect 52 positive cases.
Five studies assessed the cost-effectiveness of screening for HBV among migrants, in a
hypothetical immigration cohort in Canada [19, 20]; in migrants from countries with high and
intermediate HBV prevalence compared with the status quo in the Netherlands [18]; in immi-
grants from countries with high HBV prevalence in the US [17]; and in Asian and Pacific
Islanders living in the US [16]. In particular, Hutton et al took into account potential vertical
Fig 1. Selection of studies on cost-effectiveness of HBV screening until November 2011.
doi:10.1371/journal.pone.0145022.g001
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transmissions of mother to infants [16]. In four studies, incremental cost-effectiveness analyses
were carried out, and the incremental costs per QALY gained between strategies were estimated
[16, 18–20]. Rein et al based their analysis on six months of observational data. The cost per per-
son screened was calculated, but no formal cost-effectiveness analysis was undertaken [17].
Screening and treating Asian and Pacific Islanders was shown to be a cost-effective strategy com-
pared with the status quo [16]. Incorporating screening and treatment of close contact individu-
als of those tested positive also showed cost-effective results (ICER of $39,903 per QALY gained)
[16]. Similarly, screening adult migrants soon after arrival in Canada for chronic HBV and pro-
viding antiviral treatment was shown to be cost-effective with an ICER of 40,880 Canadian dol-
lars per QALY gained [20]. The remaining studies showed similar favourable results.
Various screening strategies were evaluated in newborns, preadolescents and adolescents
including: pre-vaccination testing [22], primary prevention and screening [21], vaccinating
high risk groups [23]. These were compared to an array of comparators, such as: ‘do nothing’,
prenatal screening and subsequent vaccination of newborns at risk, universal vaccination of
infants, school children and adolescents [21–23]. These studies either used a decision tree [22,
23] and compartmental and Markov models [21]. Conclusions on cost-effectiveness were
mixed and difficult to generalise as studies used a range of outcome measures, making it diffi-
cult to compare between studies.
Critical appraisal of economic models–Hepatitis B Virus
The checklist developed by Philips et al was completed for those studies that used an economic
model to estimate cost effectiveness of screening (n = 13). The associated performance matrix
(Fig 3) shows results for each individual study and their performance in each of the twelve dis-
tinct categories of the checklist. Overall, the quality of the models varied greatly. There are
Fig 2. Selection of studies on cost-effectiveness of HBV screening; September 2011 until July 2015.
doi:10.1371/journal.pone.0145022.g002
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Table 1. Summary of Cost-Effectiveness Results- HBV.
Study Strategies Compared Prevalence Costs for Strategies Outcomes for
Strategies
ICER
Antonanzas,
1995
Mass immunisation of
adolescents
Do nothing Varied by
age
N/A N/A N/A
Mass immunisation of
infants
Do Nothing Varied by
age
N/A N/A N/A
Combined mass
immunisation
Do Nothing Varied by
age
N/A N/A N/A
Screening all women during
pregnancy combined with
above strategies
Do Nothing Varied by
age
N/A N/A N/A
Arevalo,
1988
Screening & vaccination (at
birth and repeated hepatitis
vaccine at months 1 and 6)
Do Nothing 0.2% $1,157,000 $7,950,000 Cases
prevented2-
140
0 N/A
Bloom, 1993 Screening & Vaccination
High risk newborns and all
adolescents
Do Nothing Not provided 27.8 0 $3,695 per
LYG
Screening & Vaccination
General adult population
Do Nothing Not provided 4.8 0 $279,184
per LYG
Screening & Vaccination
High risk adults
Do Nothing Not provided 32.6 0 Cost saving
Screening & Vaccination
Newborns
Do Nothing Not provided 18.5 0 $42,067 per
LYG
Vaccination all adolescents Do Nothing Not provided 13.9 0 $97,256 per
LYG
Vaccination General adult
population
Do Nothing Not provided 5.8 0 $257,418
per LYG
Vaccination High risk adults Do Nothing Not provided 52.5 0 Cost saving
Vaccination Newborns Do Nothing Not provided 17 0 $38,632 per
LYG
Eckman,
2011
Screen and treat with low
cost nucleoside/ nucleotide
(general population)
No screening 0.4% $1,177.963 $914.76 23.2319 23.2228 $29,232 per
QALY
gained
Hutton, 2007 Screen, treat and ring
vaccinate, Immigrants
(Asian and Paciﬁc
Islanders)
Screen and
treat
10% $868,612,000 $866,204,000 237,909 237,849 $39,903 per
QALY
gained
Screen and treat
Immigrants (Asian and
Paciﬁc Islanders)
Status quo 10% $866,204,000 $846,008,000 237,849 237,289 $36,088 per
QALY
gained
Kim, 2006 Routine Vaccination (CTSs)
-(General population of high
risk adults)
No Intervention Not
speciﬁed
$680,000 $0 155 0 $4,400 per
QALY
gained
Screening & Vaccination Routine
Vaccination
$850,000 $680,000 61 155 Dominated
Screening with initial dose Routine
vaccination
$680,000 $1,220,000 152 155 Dominated
Routine Vaccination (STD
clinic)—(General population
of high risk adults)
No Intervention $740,000 $0 214 0 $3,500 per
QALY
gained
Screening & Vaccination Routine
Vaccination
$960,000 $740,000 107 214 Dominated
Screening with initial dose Routine
vaccination
$1,320,000 $740,000 209 214 Dominated
Kwan-Gett,
1994
Pre-vaccination testing N/A Not
speciﬁed
N/A N/A N/A
(Continued)
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Table 1. (Continued)
Study Strategies Compared Prevalence Costs for Strategies Outcomes for
Strategies
ICER
Test & Vaccinate N/A N/A N/A N/A
No Testing N/A N/A N/A N/A
Mulley, 1982 No Intervention (MSM) n/a 5% N/A N/A N/A
Rein, 2011 Model 1 N/A 1.7% /6.3% Cost per case identiﬁed: $609 N/A N/A
Model 2 N/A 1.7% /6.3% Cost per case identiﬁed: $1,584 N/A N/A
Model 3 N/A 1.7% /6.3% Cost per case identiﬁed: $3,150 N/A N/A
Model 4 N/A 1.7% /6.3% Cost per case identiﬁed: $4,657 N/A N/A
Ruggeri,
2011
Test (high risk population) No Test 7% €67,007.73 €7,939.39 20.07 16.63 €18,255.97
per QALY
gained
Thomas,
1990
Universal screening during
pregnancy
N/A Per carrier identiﬁed:$354 N/A N/A
Screening of high risk
women during pregnancy
N/A Per carrier identiﬁed:$97 N/A N/A
Screening of low risk
women during pregnancy
only
N/A Per carrier identiﬁed:$2,005 N/A N/A
Tormans,
1993
Screening & vaccination
during pregnancy
Do nothing 0.67% BEF31,719,490 BEF
6,800,587
5.93 (LYL) 48.63
(LYL)
BEF
583,581 per
LYG
Veldhuijzen,
2010
One-off systematic
screening and treatment of
eligible patients
(immigrants)
Status quo of no
screening
3.35% €168,480,000 €109,178,000 120,025 113,411 €8,966 per
QALY
gained
Wong, 2006 Screen & Treat (Tenofovir) No screening 4.81% $(CAD)74,911 $ (CAD)
73,246
16.17 16.15 $ (CAD)
69,209 per
QALY
gained
Screen, treat & vaccinate
(Tenofovir)
Screen & Treat 4.81% $(CAD)74,992 $(CAD)
74,911
16.17000022 16.17 $(CAD)
3,648,123
per QALY
gained
Screen & Treat (Entecavir) No screening 4.81% $(CAD)75,380 $(CAD)
73,352
16.17 16.15 $(CAD)
101,513 per
QALY
gained
Screen, treat & vaccinate
(Entecavir)
Screen & Treat 4.81% $(CAD)75,447 $(CAD)
75,380
16.1700028 16.17 $(CAD)
241,983 per
QALY
gained
Zurn, 2000 Universal school children
vaccination
Systematic
screening &
selective
vaccination
5% Not speciﬁed Not speciﬁed SwF10,200
per LYG
Universal vaccination of
infants
Systematic
screening &
selective
vaccination
5% Not speciﬁed Not speciﬁed SwF6,120
per LYG
Universal school children
vaccination
Universal
vaccination of
infants
5% Not speciﬁed Not speciﬁed SwF10,480
per LYG
(Continued)
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however common trends, with more recent studies performing better than earlier studies.
Model inputs were generally consistent with the stated perspective which included that of the
payer (taking into account direct medical costs) or that of the society (taking into account
direct medical costs and costs to the individuals being screened or vaccinated). Although the
costs for carrying out screening of patients were included in the analyses, most studies
neglected the costs associated with various screening efforts (i.e. costs associated with efforts of
recruiting patients).
Data sources used to develop the structure of the model were usually specified, but studies
rarely reported whether the quality of the data used in the models had been assessed. Studies
mainly sourced their data from the literature but also used expert opinion [21, 23]. Studies gener-
ally provided a graphical representation of a model, which showed the transition of individuals
between health states or the key alternatives of the decision (screening strategy) and its associated
consequences. A number of studies either did not report their time horizon or used a time hori-
zon which was judged not to be sufficient to reflect all important differences between the options
under evaluation [14, 15, 21, 22]. Further variations that were not accounted for by study location
were found in the discount rates used for future costs and benefits.
Results for any cost-effectiveness analyses depend on assumptions made during the model-
ling process and key assumptions are summarised below.
Prevalence estimates are difficult to obtain as the underlying prevalence in a population is
unknown and studies frequently relied on estimates obtained from national surveys or the pub-
lished literature. With prevalence being the main driver of cost-effectiveness results, interpreta-
tion always needs to be made in relation with the prevalence rate employed in the model.
Sensitivity of the model results to the level of prevalence, was not always tested.
Assumptions made on the protection rate of a vaccine and assumptions made on the pro-
portion of individuals protected from HBV by virtue of a previous infection are important.
Limitations were identified in one study’s ability to capture the full benefits and limitations of
vaccination such as the indirect effects of herd immunity [19]. The intensity of the infection,
which was assumed to be constant, and the annual probability of acquiring HBV infection,
which was also assumed to be constant, were both identified as important parameters in
another study [16]. With both, the assumption of a constant rate was found to limit the study’s
ability to infer precise cost-effectiveness results [16].
Table 1. (Continued)
Study Strategies Compared Prevalence Costs for Strategies Outcomes for
Strategies
ICER
Universal vaccination of
adolescents
Universal
vaccination of
infants & school
children
5% Not speciﬁed Not speciﬁed SwF10,480
per LYG
Rossi, 2013 Universal vaccination Do nothing 6.5% $5,472 $5,429 21.7462
QALYs
21.7463
QALYs
Dominated
Screening for prior immunity
and vaccination
Do nothing 6.5% $5,485 $5,429 21.7462
QALYs
21.7463
QALYs
Dominated
Chronic HBV screening and
treatment
Do nothing 6.5% $6,077 $5,429 23.6292
QALYs
21.7463
QALYs
$40,880 per
QALY
Combined screening for
chronic HBV and prior
immunity, treatment and
vaccination
Chronic HBV
screening and
treatment
6.5% $6,101 $6,077 23.6293
QALYs
23.6292
QALYs
$437 per
QALY
doi:10.1371/journal.pone.0145022.t001
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In addition, compliance rates together with the length of efficacy of the vaccine (e.g. 10
years) and efficacy of the treatment were found to impact on the disease part of the economic
model [20]. It was further assumed that vaccines do not incur any side effects that required
medical care, thus impacting in particular on the treatment costs. Studies have made simplify-
ing assumptions on test sensitivity and specificity [8]. Although standards should apply for
these values, variations might be found depending on whether tests are carried out correctly.
This would impact on the proportion of patients correctly identified with the virus and referred
for treatment. Further limitations extend to the fact that death unrelated to HBV was not
always included.
Cost-effectiveness analyses of screening for HCV
The search (up until November 2011) identified 1,973 references of which 19 studies met the
inclusion criteria and were included in the review (Fig 4). The updated search in July 2015
returned a total of 420 references of which 12 studies were added to the review (Fig 5). The
Fig 3. Performance Matrix—HBV screeningmodels.
doi:10.1371/journal.pone.0145022.g003
Cost-Effectiveness of HBV and HCV Screening
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majority of studies evaluated the cost-effectiveness of screening for HCV in Europe or the US;
one study was carried out in Japan. Fourteen studies evaluated screening in the general popula-
tion [24–37]; 13 studies investigated screening IDUs [24, 26, 27, 38–47]; three studies looked at
recipients of blood transfusions [26, 27, 48]; two studies evaluated screening in women during
pregnancy [49, 50], while one study included first-generation pregnant migrants from non-
Western countries [50], one study evaluated cost-effectiveness of screening migrants [51], one
looked at HIV positive MSM [52] and a further study looked at HCWs [53]. It has to be noted
here, that a number of studies evaluated the cost-effectiveness of HCV screening in multiple
population groups (i.e. 22 studies reported on 26 cost-effectiveness analyses in five population
groups).
Results of all cost-effectiveness analyses have been summarised and are shown in Table 2.
Detailed results for data extraction can be found as S2 Table.
Studies evaluating cost-effectiveness of screening in the general population were carried out
in a range of countries and healthcare settings including hospital or secondary care [25, 28],
primary care [29, 38, 50] or community settings [34, 47]. Screening interventions often com-
bined different strategies, including combinations of ELISA and PCR testing [26, 29] and test-
ing individuals with increased ALT levels [25]. Most studies evaluated a one-off screening
intervention, with the exception of one study that analysed screening every five years [28].
Linas et al evaluated ten screening strategies, including symptom-based screening and liver
function tests (LFTs) at various intervals combined with HCV Ab tests [52]. Comparators were
either no screening or the status quo [26, 28, 29, 37, 50, 51] or strategies were compared with
each other [25, 38]. More recent studies have concentrated on birth cohort screening in the US
[32, 33, 35], evaluating the cost-effectiveness of one-off screening for a cohort born between
1946 and 1970 [32], a cohort born between 1945 and 1965 [33] and all adults aged 40 to 74
year, who are unaware of their HCV infection status [35]. HCV prevalence in this population
Fig 4. Selection of studies on cost-effectiveness of HCV screening until November 2011.
doi:10.1371/journal.pone.0145022.g004
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was comparatively high. The initiation of a one-off screening intervention was assessed and
compared with current risk-based screening interventions.
Most studies used a decision tree to reflect the screening arm of the intervention, followed
by a Markov model to present the disease module [26–29, 31, 32, 34–36, 47, 51]. Some studies
employed a Markov model only [33, 36, 37, 50] and two studies did not use a model to evaluate
the cost-effectiveness of screening for HCV [25, 38].
Conclusions about cost-effectiveness of individual screening strategies were mixed for the
general population. This reflects the evolving approaches to treatment and management over
time. Treatment regimes have been changing rapidly over the last years and recent models
have used interferon-free DAA treatments [37], so when interpreting results, a distinction
needs to be drawn between main treatment strategies, i.e. IFN/RBV models, triple therapy
(IFN/RBV+telaprevir or boceprevir) and IFN-free DAAs. Apart from new treatment regimes,
recent studies in the US showed birth cohort screening to be cost-effective when compared
with risk-based screening, but only one of these was able to include these new treatment
options [35] and the remaining studies included standard treatment. However all studies
showed favourable cost-effectiveness results which are mainly due to the very high prevalence
in this particular birth cohort in the US. People will have lived with undetected HCV infection
for a long time, so will be at a more advanced stage of infection, when detected, rendering treat-
ment to be more effective. In general, the results of the studies were found to be sensitive to
assumptions made on prevalence in the general population, and discount rates applied to
future costs and benefits. In addition to the underlying prevalence of HCV infection, studies
identified the annual rate of progression from chronic HCV to cirrhosis as an important factor
Fig 5. Selection of studies on cost-effectiveness of HCV screening; September 2011 until July 2015.
doi:10.1371/journal.pone.0145022.g005
Cost-Effectiveness of HBV and HCV Screening
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that substantially influenced cost-effectiveness results as well as the loss of quality of life associ-
ated with the knowledge of HCV infection.
A total of ten papers evaluated cost-effectiveness of screening IDUs; four in the UK [24, 40,
41, 44], two in France [26, 27]; one in Italy [45] and three in the US [38, 46, 47]. Settings
included primary care, prison services and substance abuse treatment centres. Screening was
performed as one-off screening in all studies, with a strategy of ‘no screening’ frequently serv-
ing as the comparator. Thompson-Coon et al analysed two different approaches within a for-
mer IDU population; a population approach and a targeted approach [44]. Tramarin et al
evaluated the cost-effectiveness of screening, and compared two strategies which followed the
incident IDU population over time using two scenarios, chronic and acute infection [45]. More
recently, Cipriano et al evaluated screening IDUs for both, HCV and HIV infection simulta-
neously [46]. Schackman et al also investigated various screening strategies, one of them also
combining HCV and HIV screening of IDUs [47]. The majority of studies employed a decision
tree followed by a Markov model [24, 26, 27, 41, 44, 47]; one study used a Markov model only
[45] and Cipriano et al employed a dynamic model [46]. Leal et al used a decision tree analysis
[40]. Honeycutt et al did not use an economic model and presented an average cost-effective-
ness ratio per person who returned to receive their results using a multiplicative formula [38].
Two UK studies reported screening and treating IDUs in one prevalent round of screening
to be cost-effective compared to no screening, in a UK context. However, there were substantial
differences in estimated ICERs– £28,120 per QALY gained using a decision tree followed by a
Markov model and discounting of costs and benefits [41] and £9,300 per QALY gained based
on a decision tree analysis of a hypothetical cohort of IDUs only discounting future costs [40].
Studies concluded that screening is likely to be most cost-effective in individuals whose infec-
tion is more long-standing and who would be at higher risk of progression [24] [44]. Tramarin
et al evaluated screening strategies for different genotypes and concluded that screening domi-
nated the no screening strategy for genotypes 1 and 4, but for genotypes 2 and 3, screening
would cost €9,659 per QALY gained compared to no screening [45]. Similar to the general pop-
ulation, faster progression rates were found to result in more favourable cost-effectiveness
ratios, mainly due to benefits being incurred much earlier [43]. In general, studies were in
agreement that screening IDUs in various settings (mainly prison) is cost-effective compared
to a strategy of no screening. Cost-effectiveness results were sensitive to the assumptions on
prevalence of HCV, in particular for the difficult to treat genotypes, and on progression rates.
Using interferon-free regimens as one of their treatment options, Schackman et al estimated
an ICER of $27,100 per QALY gained for rapid on-site testing for HCV compared to no testing
and an ICER of $64,300 per QALY gained for rapid on-site testing for both, HCV and HIV
compared to on-site rapid HCV testing alone [47].
Loubiere et al assessed cost-effectiveness of five strategies of varying tests of screening blood
recipients and combined these with two different treatment strategies that would follow after a
positive diagnosis [27]. Jusot and Colin compared the cost-effectiveness of screening for HCV
with no screening in recipients of blood donations [48]. A decision tree followed by a Markov
model was employed in two studies [26, 27]. A similar approach to the decision analytical
model was used by Jusot and Collin [48]. The studies were in general agreement that screening
blood recipients for HCV infection was unlikely to be cost-effective as the high prevalence in
this population is off-set by higher mortality rates.
Two studies compared strategies for screening women during pregnancy [49, 50]. Plunkett
et all compared three strategies: (i) routine screening followed by a 48-week course of treat-
ment; (ii) routine screening followed by a 48-week course of treatment and elective caesarean
delivery; (iii) usual care (no screening) [49]. The evaluation was based on a decision tree sup-
plemented by a Markov model. Screening followed by treatment was found to be dominated
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(more costly and less effective) by usual care. Similarly, screening followed by treatment plus
elective caesarean delivery was shown not to be cost-effective when compared with usual care
(ICER of $1,170,000 (USD) per QALY gained). The ‘no screening’ strategy continued to domi-
nate even when a higher prevalence (up to 10%) was assumed. Urbanus et al evaluated screen-
ing strategies for two groups in the Dutch setting: i) all pregnant women and ii) first-
generation pregnant migrants from non-Western countries [50]. The authors based their eval-
uation on a Markov model and found that screening followed by standard treatment for all
pregnant women would cost €52,473 per LYG compared to no screening. Screening non-West-
ern pregnant women, followed by the same treatment regime, would cost €47,113 per LYG.
When protease inhibitors were added to standard treatment, screening was found not to be
cost-effective in a Dutch setting with ICERs of €88,162 and €86,005 per LYG [50].
Screening of HCWs was evaluated comparing four strategies (‘French recommendation’,
‘European recommendation’, ‘baseline US recommendation’ and ‘alternative US recommenda-
tion’) following occupational exposure in France [53]. Both, the European and French strategy,
were dominated by other strategies in the analysis. Compared with the baseline US strategy,
the alternative US strategy showed an ICER of €2,020 per QALY gained.
Linas et al evaluated screening HIV infected MSM for HCV using a combination of different
screening strategies: symptom-based screening and liver function tests (LFTs) at various inter-
vals with/without HCV Ab tests [52]. Employing a Monte Carlo simulation model (‘HEP-CE’)
to estimate cost-effectiveness of screening, the authors compared each strategy to symptom-
based screening alone. They concluded that screening for acute HCV in HIV infected MSM
using six-monthly LFTs and a 12-months HCV Ab test would cost $43,700 per QALY gained
compared to symptom-based screening combined with IFN/RBV. Adding protease inhibitors
to this strategy resulted in an ICER of $57,800 per QALY gained [52].
A recent study from the UK evaluated cost-effectiveness of screening migrants from the
Indian sub-continent [51]. Participants were invited via an opt-out strategy and subsequently
invited for screening. The study employed a Markov model to evaluate cost-effectiveness and
concluded that opt-out GP case finding was potentially cost-effective with an ICER of £23,200
per QALY gained compared to no intervention, but there was a substantial degree of uncer-
tainty surrounding these estimates. Increasing the treatment costs and adding boceprevir or
telaprevir to treatment did not change these results [51].
Critical appraisal of economic models–Hepatitis C Virus
The checklist developed by Philips et al was completed for all studies that used an economic
model to estimate cost-effectiveness of screening (n = 26). The associated performance matrix
(Fig 6) shows results for each individual study and their performance in each of the twelve dis-
tinct categories of the checklist. The pattern in the matrix shows that those studies published
more recently performed better. Model inputs were found to be consistent with the stated per-
spective of the model; however, some studies broadly claimed to have adopted a societal per-
spective, while only considering direct medical costs. In general, studies provided a clear
presentation of the model structure with only a few studies presenting just the Markov part of
the model. Similar to some HBV studies, one major limitation relates to the way ICERs were
estimated. When multiple strategies were evaluated, although all studies presented incremental
analyses for synthesising costs and benefits, some studies presented a series of pairwise com-
parisons against a common comparator, for instance the status quo or no screening, rather
than a fully incremental analysis.
Although the majority of studies employed discounting for costs and effects, the choice of
rates was frequently not justified. In most cases rates would be chosen according to current
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policy guidelines and, as a result, authors may not have felt the need to provide additional justi-
fication. Studies with a short time horizon (< 1 year) did not apply any discounting. In general,
studies performed well against the requisite criteria. With regard to sensitivity analysis, the
majority of studies employed one-way sensitivity analyses to assess parameter uncertainty.
Broadly, cost-effectiveness of screening for HCV was relatively insensitive to variations in
most of the input parameters, such as the cost of screening and treatment. However, Urbanus
et al showed that adding protease inhibitors to standard treatment regimes altered conclusions
about the cost-effectiveness of screening pregnant women [50]. Overall, the parameter that
cost-effectiveness results were most sensitive to was the prevalence in the target population,
including varying prevalence rates in different genotypes. For general population studies,
assumptions on prevalence rates varied from 0.9% (women) [38] to 6.5% (men) [25]. Preva-
lence estimates for IDUs ranged from 12.5%[44] to 80% [26] and for blood transfusion recipi-
ents rates varied between 3% [48] to 7% [25]. The prevalence rate that was used for evaluating
screening in migrants was 3.2%, which was varied between 1% and 5% in sensitivity analyses
[51], and 9.8% was used by Linas et al, to evaluate cost-effectiveness of screening HIV positive
MSM for HCV [52]. Prevalence of HCV infection in HCWs has not been used as a parameter
in the analysis; however this is most likely to be reflected in transmission risk from patients to
HCW during occupational exposure. Several studies showed in sensitivity analyses that their
cost-effectiveness results changed considerably when the prevalence rate was varied. Stein et al
showed that estimated costs per QALY increased rapidly once the underlying prevalence in the
population likely to attend GUM clinics decreased below 3% [37].
Cost-effectiveness results are also sensitive to the assumptions made on prevalence of HCV
for the difficult to treat genotypes and to progression rates from chronic HCV to cirrhosis and
Singer et al found that for screening to be cost-effective this rate should be greater than 2.5%
[36]. Another important factor that would impact on cost-effectiveness results was the loss of
quality of life (disutility of knowledge of HCV infection) which was assumed to be 0.02 in the
baseline scenario. Even for a disutility of 0.01, the ‘no screening’ option remained the preferred
strategy [36]. Furthermore, the staging of liver disease was found to impact on cost-effective-
ness results. Identifying individuals with more advanced infection yielded more favourable
cost-effectiveness results than screening and detecting those in the early stages of the disease.
Variation in the discount rate had a considerable impact on cost-effectiveness results. Further
assumptions, although less important in terms of cost-effectiveness results, were made on
Fig 6. Performance Matrix—HCV screeningmodels.
doi:10.1371/journal.pone.0145022.g006
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transmission risks, in particular in those studies evaluating screening strategies for pregnant
women.
The associated PRISMA checklist can be found in the S3 Table.
Discussion
For both, HBV and HCV screening, studies used various economic models in order to derive
their cost-effectiveness conclusions, but the overall approach was relatively consistent across
studies. For example, disease states represented in the various models did not differ fundamen-
tally and the overall model structure was found to be consistent. Where models were found to
differ, however, was the screening component which varied between studies depending on
interventions examined, such as universal screening and targeted or risk-based screening.
Models were also found to vary in assumptions made on the input parameters, population, and
outcome measures to express cost-effectiveness results. The critical clinical input parameters
that were identified include: prevalence, test sensitivity and specificity and treatment effective-
ness. Most studies focussed on direct medical costs adopting a healthcare payer perspective,
while some studies also took account of costs associated with loss of productivity, adopting a
societal perspective. The population groups evaluated did not show any major gaps in terms of
certain risk-groups that were not included. On the contrary, the review showed that some of
the populations studied in the past should not be the focus of future research as there is evi-
dence that screening does not offer a cost-effective result- this is the case in particular for HBV
screening, where there was very little recent literature and the existing evidence suggests that it
might only be a cost-effective strategy in migrant populations and not in other population
groups, such as the general population. This overall result was not altered by the use of different
economic models. Various outcome measures were used, including QALYs, life-years gained,
the number of cases detected and the number of infections prevented. Discount rates varied,
both between countries in which the studies were carried out, but also within countries and
over time. Any results obtained from older studies, applying discount rates that have been
updated since, should therefore be interpreted with care.
The treatment landscape for HCV has been changing dramatically. With the advent of
direct acting antiviral therapy in 2008/09, first generation interferon-containing regimens sub-
stantially increased the efficacy in genotype 1 patients [54]. Even more effective, shorter dura-
tion, more tolerable, and interferon-free regimes have recently become available. These new
treatments come at a higher cost but are generally believed likely to increase treatment uptake.
Earlier studies have modelled their costs and outcomes on the basis of Interferon + Ribavirin
or Peg INF/Ribarivin, while more recent studies will have modelled on the basis of Peg INF +
Ribavirin and DAAs. The most recent studies are now looking at IFN-free DAAs with Wong
et al showing that screening and treatment using IFN-free DAAs would likely be cost-effective
[37]. Thus, the focus should be on those more recent studies, which applied the latest treatment
regimes, test methods and had more data on which to base their models. Findings from older
publications need to be interpreted with caution as there could be a potential relationship
between the age of the study and the assumed treatment effectiveness and cost.
Studies have pre-dominantly used static models, not accounting for the dynamic transmis-
sion element of the infection and any potential treatment as prevention benefit, in particular
for HCV [24–29, 38–41, 43, 48, 53]. Studies employing a static Markov model structure include
progression of the disease in an individual, and either no re-infection or re-infection at a fixed
rate through time irrespective of population prevalence. The use of a dynamic transmission
model assumes the risk of an individual’s infection is related to the population prevalence,
which may change through time with screening and treatment [46]. The use of a dynamic
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model increases the complexity, but allows for the inclusion of the possible population benefits
of screening and treatment on transmission, in addition to the individual benefits. However,
dynamic models require an understanding of the disease epidemic and modes of transmission.
Conclusions
Overall, published modelling strategies for HBV and HCV screening do not differ fundamen-
tally. Future models evaluating the cost-effectiveness of screening for HBV and HCV infections
should concentrate on selection of the most relevant input parameters, (i.e. those to which
cost-effectiveness results are most sensitive) and the selection of those population groups for
which screening has been shown to be cost-effective. In addition to prevalence, understanding
disease incidence is important as it impacts on the frequency of testing high-risk populations.
Careful consideration of dynamic versus static modelling is also recommended. A dynamic
model structure includes benefits of the prevention of the transmission from either cured indi-
viduals or benefits of averted transmission due to knowledge about their infection. It therefore
accounts for direct effects on the infected individuals and also indirect effects of protecting
other persons, such as sexual or injecting partners, in the future. Hence, future research should
concentrate on these methodological issues. In particular, more consideration should be given
to the evaluation of screening strategies for multiple infectious diseases, such as HCV and HIV
simultaneously as well as birth-cohort screening. Birth-cohort screening has shown a favour-
able ICER compared to risk-based screening, mainly due to the fact that individuals will have
lived with the infection being undetected for a number of years, so that treatment will be more
effective in these advanced stages of infection. So far, these have only been assessed in a US
context, and the evaluation of birth-cohort screening in a European context would be valuable
as the age structure might differ.
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